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Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128 S117Adenosine A2A receptor (A2AR) have been reported to
promote T cell tolerance in several in vivo models, particu-
larly in the GVHD setting; however it’s role in engraftment is
unclear. In this study, we examined the ability of an A2AR
agonist to promote engraftment in a murine allogeneic bone
marrow transplantation model. B6D2F1/J recipients were
conditioned with 300 cGy and transplanted 24 hours later
via lateral tail vein infusion with 2106 T-cell depleted bone
marrow cells from C57BL/6J (B6) donor cells (H2kb into H2kb/
d). Recipients received an A2AR agonist orally in a chow
formulation (1000 mg/kg/day) beginning 2weeks before cell
infusion and continuing for 9 weeks post transplantation. A
second cohort also received the A2AR agonist using osmotic
pumps (100 ng/kg/min) placed subcutaneously 48 hours
prior to cell infusion, for 28days post transplantation as well
as orally via the chow for the same time as the ﬁrst group. A
non-treatment transplant group was used as a control.
There was no apparent toxicity from the radiation or the
drug, and all animals maintained normal blood counts
throughout. Engraftment was observed in only the A2AR
agonist treated groups and a 13 fold higher level of engraft-
ment in themice treated both subcutaneously and orally was
observed. This engraftment appeared to be long term as the
mice were followed out 5 months post transplant with all
mice surviving.
As a possible mechanism of this effect, we measured the
level of CXCR4 expression on the donor bone marrow cells
(Lin-) in vitro and observed that A2AR agonist (10 mM) treat-
ment increased CXCR4 expression 1.6 fold compared to non-
treatment on donor cells in vitro. To further investigate the
effect of the A2AR agonist on engraftment, we are now
repeating the same type of transplant using an A2AR Knock
out mouse strain as the donor. We are also assessing the
levels of SDF-1 in the serum of the recipients.
These preliminary results demonstrate that A2AR agonists
may improve engraftment by increasing homing of the donor
cells without increasing the risk of graft versus host disease
and may be a signiﬁcant addition to transplant regimens.
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18-30 43% 2.95 80% 8.54
31-40 39% 2.88 0.188 80% 8.15 0.002
41-50 32% 2.83 0.052 75% 7.66 < 0.0001
51-60 25% 2.96 0.906 72% 6.78 < 0.0001
18-60 (M) 42% 2.84 85% 8.54
18-60 (F) 35% 3.05 0.004 65% 7.59 < 0.000116
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Background: Be The Match Registry facilitated over 3,300
peripheral blood stem cell (PBSC) transplants and over 1,000
bone marrow (BM) transplants in 2011. The dose of CD34þ
cells for PBSC and total nucleated cell (TNC) count for BM
impact engraftment after unrelated allogeneic transplant.
This study was performed to evaluate the frequency of
unrelated donor PBSC and BM collections that meet the
transplant physician’s requested dose and the role of the
potential donor factors including age and gender.
Methods: A cohort of 1,020 BM and 3,469 PBSC collections
from June 2011 through September 2012 were analyzed to
compare whether the collected cell dose achieved therequested dose. Male and female donors were stratiﬁed in
age groups according to their age at the time of collection
(18-30, 31-40, 41-50, 51þ) and assessed for the frequency
their donated product met the requested cell dose and the
number of cells collected per kg of donor weight.
Results: Of 1,020 BM collections analyzed, a median cell dose
of 5.0 x 10
ˇ
8 TNC/kgwas requestedwith amedian cell dose of
4.2 x 10
ˇ8 TNC/kg collected, resulting in 403 (39.5%) meeting
the requested TNC dose. Of 3,469 PBSC collections, a median
cell dose of 5.0 x 10
ˇ6 CD34þ/kg was requested with
a median cell dose of 8.1 x 10
ˇ6 CD34þ/kg collected, resulting
in 2,740 (79.0%) meeting the requested CD34þ dose.
Increasing donor age resulted in a reduction of the donor’s
ability to supply the requested dose for both PBSC and BM
collections. A statistically signiﬁcant reduction in the number
of cells collected per kg of donor weight was observed for
PBSC collections, but not BM collections (Table 1). In
addition, male donors met the requested cell dose more
frequently than female donors for both BM (42% vs 35%)
and PBSC (85% vs 65%) collections, as well as providing
a signiﬁcantly larger CD34þ cells/kg donor weight for PBSC
(8.54 vs 7.59).
Conclusions: This study shows that younger donor age
results in an increased likelihood of meeting the transplant
physician’s requested TNC or CD34þ dose. Lower donor age
also increases the CD34þ cells/kg that are obtained from
PBSC collections but not the TNC/kg obtained from marrow
collections. In addition, male donors provided increased
CD34þ cells/kg donor weight than female donors. Transplant
center practice is often to select young male donors for
patients, and this data provides evidence to support that
such practice may increase the likelihood of a providing
a product meeting a center’s request.17
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CIBMTR reported that severe thalassemia patients older
than 7 years with hepatomegaly (> 2 cm below costal
margin) achieved poor outcome after transplant; DFS ¼ 55%
since they had high rejection and mortality rates (Blood,
2011). We therefore developed the novel reduced toxicity
conditioning (RTC) regimen to overcome these problems.
Fifteen severe thalassemia patients, median age 17 years;
Table
Patient
Number
Disease
Stage/Age
Engrafted
CBU
Engraftment
Day
NiCord
Chimerism*
Months
post
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hepatomegaly. Median ferritin level was 3,500 ng/mL. All of
them received hydroxyurea (20 mg/kg/day) for at least 6
months. They also received sequential immunoablative
regimen consisted with 2 monthly cycles of ﬂudarabine 40
mg/m2 and dexamethasone 25 mg/m2 x 5 days prior to
conditioning regimen. The conditioning regimen consisted
with busulfan 130 mg/m2 x 4 days, ﬂudarabine 35 mg/m2 x 6
days and ATG 6 mg/kg. GVHD prophylaxis consisted with FK
506 or cyclosporine and MMF. All of them received periph-
eral blood stem cells with a target dose of CD34þ10 x 106
cells/kg. Eleven patients received matched related and 4
receivedmatched unrelated donor stem cells. Median time of
neutrophil and platelet engraftment was day þ10 and þ 15
respectively. Three patients had mild VOD. Four patients had
grade II-IV and none had grade III-IV GVHD. Five patients had
mild chronic GVHD which subsequently was resolved. All 15
patients achieved full (100%) donor chimerism at day þ30
and these chimerisms were sustainable. Overall and disease
free survival rates were 91.2 % (95%CI:50-96). No rejection
was observed. One patient died from cerebellar hemorrhage.
We suggest that our sequential immunoblative regimen prior
to conditioning regimen is a key factor for this favorable
outcome in these difﬁcult patients. We also proved that T cell
proliferation assay (stimulationwith PHA) was suppressed in
all patients after 2 cycles of sequential immunoablative
regimen. This could explain the immunoablative concept in
our study. Our novel approach may be suitable for transplant
in other non malignant diseases.Transplant
ANC
>500
Platelet
>20,000
CD15
(%)
CD3 (%)
1 AML
(CR1)/61
NiCord
þ UM
14 33 42 2 22
2 MDS
(Int-2)/43
NiCord 11 30 100 100 17
3 MDS
(Int-2)/59
NiCord 10 30 97 93 15
4 AML
(CR2)/41
UM 18 36 0 0 14
5 AML
(CR1)/57
UM 26 49 0 0 11
6 AML
(CR2)/45
NiCord 10 30 100%
(Whole
Blood)
8
7 HL/21 NiCord
þ UM
7 26 100 31 6
8 NHL/46 Graft
failure
- - - - 5z
9 AML
(CR1)/45
NiCord 14 41 97 61 2
10 AML
(PR)/59
NiCord 18 - >98
(Whole
Blood)
2y
11 ALL
(CR1)/44
NiCord 7 N/A 100 100 1
*Performed at date of last follow-up from peripheral blood.
yDeath Day 47 Pneumonia.
zRe-transplanted with haploidentical donor.18
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Human transplantation of expanded HPCs resulting in
durable, robust donor myeloid and T-cell engraftment has
yet to be reported. A pilot study of myeloablative dual UCB
transplantation where one UCB unit is expanded ex vivo
using NiCord technology has completed accrual. The NiCord
UCB graft consisted of an expanded CD133þ and an unex-
panded CD133- T-cell fraction. HPCs were expanded for 21
days in media containing cytokines supplemented with
nicotinamide (NAM). All patients were conditioned with TBI
(1350cGy), ﬂudarabine 160mg/m2 cyclophosphamide
120mg/kg (n¼2). GvHD prophylaxis consisted of tacrolimus
and MMF. Eleven patients (med. age 45; range 21-61) with
high-risk malignancies received NiCord and an UM graft
(Table). Both units were comparably HLA-matched with the
recipient; 4/6 (n¼7), 5/6 (n¼3) or 6/6 (n¼1) vs. 4/6 (n¼8), 5/6
HLA (n¼3), respectively. However, the UM unit containeda larger pre-cryopreserved cell dose (3 x 107/kg [range 1.9-
3.9] vs. 2.5 x 107/kg [range 1.7-3.8]). After expansion
(CD133þ fraction), NiCord contained a median TNC and
CD34þ cell dose of 2.7 x 107/kg (1.0-6.4) and 3.5 x 106/kg
(0.9-18.3), respectively. The NiCord T-cell dose was
substantially smaller than the UM graft.
Results: Eight patients engrafted with NiCord (one of which
is a mixed donor chimera) and twowith the UM graft (Table).
One patient experienced primary graft failure. The median
time to neutrophil engraftment was 12.5 days (7-26) for the
entire cohort, and 10.5 (7-18) days for those engrafting with
NiCord. Three patients experienced grade I/II acute GvHD.
There were no cases of Grade III/IV acute GvHD. No safety
concerns were raised. The estimated 100-day treatment-
related mortality is 10%. With a median follow-up of 8
months, the progression-free and overall survival are both
90%.
Conclusion: NiCord expanded HPC’s are capable of out-
competing those from the UM unit and predominate in the
majority of patients. NiCord expanded HPC’s reduce the time
to hematopoietic recovery and are capable of long term (>22
months) neutrophil and T-cell engraftment. Stem cell
transplantation using NiCord is feasible, and may provide
a potent cord blood graft enabling transplantation of a single
expanded unit, without co-infusion of UM cells.19
Trends in the Incidence and Spectrum of Organisms
Responsible for Bacteremia After Allogeneic Stem Cell
Transplantation Using Two Different Prophylactic
Strategies: A 12-Year Experience At Memorial Sloan-
Kettering Cancer Center
Ubonvan Jongwutiwes 1, Kun Xiao 1, Dick Chung 1,
Anindita Chakraborty 2, George I. Getrajdman 3,
Sergio A. Giralt 4, Ann A. Jakubowski 4, Susan K. Seo 1,
